Back to Search
Start Over
Antipsychotic use in pregnancy and risk of attention/deficit-hyperactivity disorder and autism spectrum disorder: a Nordic cohort study
- Source :
- Evidence-Based Mental Health, Hálfdánarson, Ó, Cohen, J M, Karlstad, Ø, Cesta, C E, Bjørk, M-H, Håberg, S E, Einarsdóttir, K, Furu, K, Gissler, M, Hjellvik, V, Kieler, H, Leinonen, M K, Nørgaard, M, Esen, B Ö, Ulrichsen, S P, Reutfors, J & Zoega, H 2022, ' Antipsychotic use in pregnancy and risk of attention/deficit-hyperactivity disorder and autism spectrum disorder : a Nordic cohort study ', Evidence-Based Mental Health, vol. 25, no. 2, pp. 54-62 . https://doi.org/10.1136/ebmental-2021-300311
- Publication Year :
- 2021
- Publisher :
- BMJ, 2021.
-
Abstract
- BackgroundAntipsychotics are increasingly used among women of childbearing age and during pregnancy.ObjectiveTo determine whether children exposed to antipsychotics in utero are at increased risk of attention-deficit/hyperactivity disorder (ADHD) or autism spectrum disorder (ASD), accounting for maternal diagnoses of bipolar, psychotic and other psychiatric disorders.DesignPopulation-based cohort study, including a sibling analysis.SettingNationwide data on all pregnant women and their live-born singletons in Denmark (1997-2017), Finland (1996-2016), Iceland (2004-2017), Norway (2004-2017), and Sweden (2006-2016).Participants4 324 086 children were eligible for inclusion to the study cohort.InterventionAntipsychotic exposure in utero, assessed by pregnancy trimester, type of antipsychotic, and varying patterns of use.Main outcome measuresNon-mutually exclusive diagnoses of ADHD and ASD. We used Cox proportional hazard models to calculate hazard ratios (HRs) controlling for maternal psychiatric disorders and other potential confounding factors.FindingsAmong 4 324 086 singleton births, 15 466 (0.4%) were exposed to antipsychotics in utero. During a median follow-up of 10 years, we identified 72 257 children with ADHD and 38 674 children with ASD. Unadjusted HRs were raised for both outcomes but shifted substantially towards the null after adjustment; 1.10 (95%CI 1.00 to 1.27) for ADHD and 1.12 (0.97 to 1.29) for ASD. Adjusted HRs remained consistent by trimester of exposure and type of antipsychotic. Comparing in utero exposure with pre-pregnancy use yielded HRs of 0.74 (0.62 to 0.87) for ADHD and 0.88 (0.70 to 1.10) for ASD. Sibling analyses yielded HRs of 1.14 (0.79 to 1.64) for ADHD and 1.34 (0.75 to 2.39) for ASD.DiscussionOur findings suggest little or no increased risk of child ADHD or ASD after in utero exposure to antipsychotics.Clinical implicationsResults regarding child neurodevelopment are reassuring for women who need antipsychotics during pregnancy.
- Subjects :
- Male
Pediatrics
medicine.medical_specialty
Autism Spectrum Disorder
medicine.medical_treatment
schizophrenia & psychotic disorders
Population
child & adolescent psychiatry
Cohort Studies
Pregnancy
mental disorders
medicine
Humans
Attention deficit hyperactivity disorder
Attention
Child
education
Antipsychotic
education.field_of_study
business.industry
Hazard ratio
medicine.disease
psychiatry
Psychiatry and Mental health
Attention Deficit Disorder with Hyperactivity
Autism spectrum disorder
Prenatal Exposure Delayed Effects
Cohort
Female
adult psychiatry
business
Antipsychotic Agents
Cohort study
Subjects
Details
- ISSN :
- 1468960X and 13620347
- Volume :
- 25
- Database :
- OpenAIRE
- Journal :
- Evidence Based Mental Health
- Accession number :
- edsair.doi.dedup.....99c1989f679ab4d4bad19aeae040af75
- Full Text :
- https://doi.org/10.1136/ebmental-2021-300311